Document text
Principal Investigator: SUBHRA MOHAPATRA
Organization: JAMES A. HALEY VA MEDICAL CENTER
Fiscal Year: 2024
Funding agency: Veterans Affairs
This proposal seeks to renew Research Career Scientist Award held by Dr. Subhra
Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2018. She is also a tenured-
full professor (part-time) at the VA-affiliated academic center- the University of South Florida. She
is the recipient of several international/national awards and recognitions including as a Fellow of
the National Academy of Inventors and a Fellow of the American Institute for Medical and Biological
Engineering. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since
2007 and has been continuously funded with the Merit Review Award focused on cancer, traumatic
brain injury (TBI), and COVID since 2016. She has been studying the basic molecular and
translational mechanisms underlying the inflammation in diverse acute/chronic diseases including
COVID-19, cancers, and TBI, all of which afflict VA population and contribute significantly to the
overall health of the Veterans. The main premise of her research program has been to
understand the mechanisms involved in the disease pathogenesis toward developing novel
diagnostic/prognostic and therapeutic approaches to treat them. Current and ongoing research
activities to be supported by this RCS Award focus on three areas. The first program centers on
the characterization of novel virus-neutralizing nanoparticles that may serve as prophylactic and/or
treatment for COVID-19 patients. In this proposal, these particles will be investigated for their potential
and validated in relevant human cellular and mouse models. She is collaborating with other VA
investigators in developing an additional project to develop novel siRNA-based prophylactic and
therapeutic approaches targeting viral replication and cytokine storm that follows acute SARS-
CoV-2 infection. The second research program focuses on the investigation of a novel
combinatorial therapeutic approach in a mouse model of moderate TBI that includes an intranasal
dendrimer-based nano-formulated siRNA treatment against a recently discovered target, CCL20 to
reduce inflammation, and a parallel treatment to promote neuroregeneration by therapy with
mesenchymal stem cells. In the third research program Dr. Mohapatra’s lab aims to investigate
and test a novel targeted oncolytic viro-cell therapy for lung cancer using the mesenchymal stem
cells infected by a respiratory syncytial virus infection, which is harmless for immunocompetent
individuals. This project uses a 3D multicell tumoroid in vitro and biopsy-derived cultures ex vivo,
which her lab has pioneered. Further, this project uses in vivo mouse models of lung cancer to
evaluate the safety and efficacy of oncolytic viro-cell therapy. The project to date has attracted
industry collaboration, which might lead to clinical trials. Overall, these highly innovative
approaches taken together are expected to lead to high-impact clinical diagnostics and therapies
for diverse diseases of Veterans and other Americans in need. Veterans have been
proportionately affected by the pandemic and are increasingly affected by the incidence of lung
cancers and TBI compared to the general population. With ~100 publications, 20 patents, an h-
index of 36 and an i-index of 85, Dr. Subhra Mohapatra is recognized nationally and
internationally for her contributions to the fields of research on cancer, neurodegenerative disease,
and viral infections. She has received substantial extramural research support including awards
from the NIH, ONR, Department of Veterans Affairs, and Florida Department of Health. It is
anticipated that the development of these effective therapeutics will greatly improve the quality of
Veteran’s healthcare.
Terms: <3-D><3-Dimensional><3D><AD related dementia><ADRD><AI Augmented><AI enhanced><AI system><Academy><Acute><Affect><Alzheimer's and related dementias><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease related dementia><American><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Appointment><Area><Artificial Intelligence><Artificial Intelligence enhanced><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><Award><Biomedical Engineering><Biopsy><Biotech><Biotechnology><Brain Trauma><Breast Cancer><CAT scan><CCL20><CCL20 gene><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 anti-viral><COVID-19 antiviral><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 therapy><COVID-19 treatment><COVID-19 virus infection><COVID19 infection><COVID19 patient><COVID19 positive patient><CT X Ray><CT Xray><CT imaging><CT scan><CV-19><Cancers><Cell Body><Cell Therapy><Cell model><Cells><Cellular model><Chemokine, CC Motif, Ligand 20><Chronic><Chronic Disease><Chronic Illness><Clinical Evaluation><Clinical Research><Clinical Study><Clinical Testing><Clinical Trials><Collaborations><Colorectal Cancer><Communicable Diseases><Computed Tomography><Computer Reasoning><Coronavirus Infectious Disease 2019><Data><Dedications><Degenerative Neurologic Disorders><Dendrimers><Dendritic Compounds><Dendrons><Development><Developmental Therapeutics><Developmental Therapeutics Program><Developmental Therapy><Diagnostic><Disease><Disorder><Drug Packaging><Drug Targeting><EXTMR><Entrepreneurial Skill><Entrepreneurship><Exodus 1><Extramural><Extramural Activities><Faculty><Florida><Funding><General Population><General Public><Graduate Education><Health><Healthcare><Hospitals><Human><Immunocompetent><In Vitro><Incidence><Individual><Industry Collaboration><Industry Collaborators><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammation><International><Investigation><Investigators><Journals><LARC><Leadership><Legal patent><Licensing><Literature><Long COVID><Long COVID-19><Long coronavirus disease><Long coronavirus disease 2019><Lung Diseases><MIP3A><Machine Intelligence><Macrophage Inflammatory Protein 3-Alpha><Magazine><Malignant Breast Neoplasm><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medical><Medicine><Mentors><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Medicine><Murine><Mus><NIH><National Institutes of Health><Nerve Regeneration><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Degenerative Diseases><Neural degenerative Disorders><Neuro-regeneration><Neurocognitive><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurologic Disorders><Neurological Disorders><Neuroregeneration><Oligosaccharides><Oncolytic><Patents><Pathogenesis><Population><Property><Publications><Pulmonary Cancer><Pulmonary Diseases><Pulmonary Disorder><Pulmonary malignant Neoplasm><RSV infection><Research><Research Activity><Research Personnel><Research Support><Researchers><Respiratory Syncytial Virus Infections><SARS-CoV-2 anti-viral><SARS-CoV-2 antiviral><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2 anti-viral><SARS-CoV2 antiviral><SARS-CoV2 infection><SCYA20><Safety><Scientific Publication><Scientist><Services><Severe acute respiratory syndrome coronavirus 2 infection><Short interfering RNA><Small Inducible Cytokine Subfamily A, Member 20><Small Interfering RNA><System><Testing><Therapeutic><Therapeutic Research><Time><Tomodensitometry><Training><Translational Research><Translational Science><Traumatic Brain Injury><United States Department of Veterans Affairs><United States National Institutes of Health><United States Veterans Administration><Universities><Veterans><Veterans Administration><Veterans Affairs><Viral><Viral Diseases><Viral Respiratory Tract Infection><Virus Diseases><Virus Replication><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><acute COVID-19><acute SARS-CoV-2 infection><acute phase of COVID-19><acute phase of SARS-CoV-2 infection><artificial intelligence augmented><bio-engineered><bio-engineers><bioengineering><biological engineering><career><catscan><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chest CT><chest computed tomography><chronic COVID><chronic COVID-19><chronic disorder><chronic novel coronavirus disease 2019><clinical diagnosis><clinical diagnostics><clinical test><college><collegiate><combinatorial><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><coronavirus disease 2019><coronavirus disease 2019 anti-viral><coronavirus disease 2019 antiviral><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus infectious disease-19><coronavirus patient><cytokine release syndrome><cytokine storm><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><determine efficacy><developmental><disease of the lung><disorder of the lung><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><enhanced with AI><enhanced with Artificial Intelligence><evaluate efficacy><examine efficacy><full professor><health care><human disease><immune competent><improved><in vivo><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibitor><innovate><innovation><innovative><long haul COVID><long haul COVID-19><long haul coronavirus disease><long haul coronavirus disease 2019><long-hauler COVID><long-hauler COVID-19><long-hauler coronavirus disease 2019><long-hauler syndrome><long-term COVID><long-term COVID-19><long-term coronavirus disease><long-term coronavirus disease 2019><longterm COVID><longterm COVID-19><longterm coronavirus disease><longterm coronavirus disease 2019><lung cancer><lung disorder><malignancy><malignant breast tumor><medical diagnostic><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><mouse model><murine model><nano><nano formulation><nano medicinal><nano medicine><nano meter scale><nano meter sized><nano particle><nano-sized particle><nanoformulation><nanomedicinal><nanomedicine><nanometer scale><nanometer sized><nanoparticle><nanoscale><nanosized particle><nanotherapeutic><neoplasm/cancer><nervous system regeneration><neural regeneration><neurodegenerative illness><neurological disease><neuroregenerative><new diagnostics><next generation diagnostics><non-contrast CT><noncontrast CT><noncontrast computed tomography><novel><novel diagnostics><novel virus><pandemic><pandemic disease><particle><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><persistent COVID-19><post COVID syndrome><post COVID-19 syndrome><post acute COVID syndrome><post acute COVID-19><post acute COVID-19 syndrome><post acute SARS-CoV-2><post acute coronavirus disease 2019><post acute coronavirus disease 2019 syndrome><post acute coronavirus disease syndrome><post acute severe acute respiratory syndrome coronavirus 2><post coronavirus disease 2019 syndrome><post coronavirus disease syndrome><post-acute phases of COVID-19><progenitor cell based therapy><progenitor cell therapy><progenitor cell treatment><progenitor therapy><progenitor treatment><prognostic><programs><prolonged COVID-19 symptoms><prophylactic><regenerated nerve><research clinical testing><senior faculty><severe acute respiratory syndrome coronavirus 2 anti-viral><severe acute respiratory syndrome coronavirus 2 antiviral><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><siRNA><stem and progenitor cell therapy><stem cell based therapy><stem cell mediated therapy><stem cell therapeutics><stem cell therapy><stem cell treatment><stem cell-based therapeutic><stem cell-based treatment><therapeutically effective><three dimensional><translation research><translational investigation><traumatic brain damage><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral infection><viral multiplication><viral replication><viral respiratory infection><virus infection><virus multiplication><virus-induced disease>